Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway

BACKGROUND: Wogonin is an encouraging choice for clinical use owing to its potent anti-tumor and anti-inflammatory effects with the high safety profile. However, wogonin for targeted therapy of lymphoma was not well addressed. In this study, we focused on its anticancer effect alongside with the und...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Wu, Xue, Liu, Ping, Zhang, Haijun, Li, Yuan, Salmani, Jumah Masoud Mohammad, Wang, Fei, Yang, Ke, Fu, Rong, Chen, Zhewei, Chen, Baoan
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5320633/
https://ncbi.nlm.nih.gov/pubmed/28222771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3145-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados